Comparative Pharmacology
Head-to-head clinical analysis: ETODOLAC versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETODOLAC versus ONMEL.
ETODOLAC vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Extended-release: 400-1000 mg orally once daily.
50 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life is approximately 6.5-7.5 hours (range 5-8 hours). With multiple dosing, the half-life remains unchanged, indicating linear kinetics. No accumulation in normal renal function.
Clinical Note
moderateEtodolac + Gatifloxacin
"Etodolac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateEtodolac + Rosoxacin
"Etodolac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateEtodolac + Levofloxacin
"Etodolac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateEtodolac + Trovafloxacin
"Etodolac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal excretion (72% as metabolites, including glucuronides and hydroxylated derivatives, less than 1% unchanged); fecal excretion (16%, primarily as metabolites); biliary excretion contributes to enterohepatic recirculation.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID